• Aethlon Medical highlighted the Hemopurifier platform, an extracorporeal blood filter designed to capture enveloped viruses and tumor-derived extracellular vesicles.
• Reported 173 treatments across 44 patients with a favorable safety profile; oncology study in Australia completed two cohorts with cohort 3 enrolling.
• Noted no dose-limiting toxicities or device-related serious adverse events at 7-day follow-ups; data readouts expected in 6-9 months.
• Outlined cash of USD 5 million as of March 31, 2026; no outstanding debt; about 2,400,000 shares outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.